Oxazoloisoquinoline derivatives as thrombin receptor antagonists
AssigneeSchering Corporation
InventorsSamuel Chackalamannil, Yuguang Wang
Life of this patent
Estimating the term…
Abstract
This application provides for oxazolisoquinoline derivatives of the formula or a pharmaceutically acceptable salt of said compound wherein: B is —CH═CH—; M is —C(R1)(R2)—; and the remaining substituents are as defined in the specification as well as pharmaceutical compositions containing them and a method of treating diseases associated with thrombosis, atherosclerosis, restenosis, hypertension, angina pectoris, arrhythmia, heart failure, and cancer by administering said compounds. This application also provides for combination therapy with the compounds of Ib or pharmaceutically acceptable salts thereof with other cardiovascular agents.
Claims8
A compound of the formula
- or a pharmaceutically acceptable salt of said compound wherein:
- B is —CH═CH—;
- M is —C(R1)(R2)—;
- n is 0 or 1;
- Het is a mono heteroaromatic group of 5 to 6 atoms comprised of 2 to 5 carbon atoms and 1 to 2 heteroatoms independently selected from the group consisting of N, O and S, with the proviso that there are no adjacent oxygen or sulfur atoms present in the heteroaromatic group, wherein a ring nitrogen can form an N-oxide or a quaternary group with an alkyl group, wherein Het is attached to B by a carbon atom ring member of the Het group, and wherein the Het group is substituted by 1 moiety, W,
- wherein W is aryl or aryl substituted by 1 to 3 substituents independently selected from the group consisting of alkyl, halogen, -Oalkyl, —CN, —CF3, and —OH;
- R1 and R2 are independently hydrogen or alkyl;
- and
- Q is
- wherein each R13 and R14 are hydrogen.
A compound of selected from the group consisting of:
- or pharmaceutically acceptable salt or thereof.
Dependencies are inferred from the claim text.